r*****b
发帖数: 305 | 1 貌似没更新了。 这两公司是不是倒闭了？
我现在有它们的股票，该怎么办？ 能抛掉吗？ 谢谢 | r*****b
发帖数: 305 | | l******3
发帖数: 1478 | 3 公司合并了。yahoo新闻都有啊。
SAN DIEGO, March 21, 2016 (GLOBE NEWSWIRE) -- Celladon Corporation (CLDN)
announced today that, based upon the final vote count certified by the
independent inspector of elections for the special meeting of stockholders
held March 21, 2016, stockholders approved all of the merger-related
proposals, including: (i) the merger and issuance of Celladon common stock
pursuant to the Agreement and Plan of Merger and Reorganization, dated
November 18, 2015, by and among Celladon, Celladon Merger Sub, Inc. and
Eiger BioPharmaceuticals, Inc., (ii) a 1-for-15 reverse stock split of
Celladon common stock and (iii) changing the name of the Company from “
Celladon Corporation” to “Eiger BioPharmaceuticals, Inc.” The reverse
stock split will become effective immediately following the close of trading
on March 22, 2016, and the closing of the merger and name change are
expected to occur immediately thereafter. The consolidated common shares
for the combined company are expected to commence trading on The NASDAQ
Global Market under the symbol "EIGR" on March 23, 2016.
“We are very pleased with the affirmative vote at today’s special meeting
of stockholders concerning our merger with Eiger and we now look forward to
closing this transaction,” stated Fredrik Wiklund, Celladon’s President
and Chief Executive Officer.
As a result of the reverse stock split, every 15 shares of Celladon common
stock outstanding will be combined and reclassified into one share of post-
closing Eiger common stock. No fractional shares will be issued in
connection with the reverse stock split. Instead, cash, based on the
closing price of Eiger common stock on the NASDAQ Global Market on the
closing date will be issued in lieu of fractions of shares.
Prior to the closing of the merger, Eiger is expected to receive gross
proceeds of $39.5 million, including the conversion of $6.0 million in
aggregate principal amount under, and all interest accrued on, convertible
promissory notes of Eiger, in investment from a combination of certain
current and new investors in Eiger. Upon the closing, each holder of Eiger
common stock will receive approximately 0.09 shares of Celladon common stock
, and upon the closing of the merger, the combined company will have
approximately 7.3 million post-reverse split shares outstanding. The Eiger
financing proceeds together with approximately $26.1 million in available,
pre-merger cash on Celladon's balance sheet, is expected to result in
approximately $59 million in cash available for the combined businesses,
before the payment of transaction and other fees. | r*****b
发帖数: 305 | 4 谢谢你。
【在 l******3 的大作中提到】
: 公司合并了。yahoo新闻都有啊。
: SAN DIEGO, March 21, 2016 (GLOBE NEWSWIRE) -- Celladon Corporation (CLDN)
: announced today that, based upon the final vote count certified by the
: independent inspector of elections for the special meeting of stockholders
: held March 21, 2016, stockholders approved all of the merger-related
: proposals, including: (i) the merger and issuance of Celladon common stock
: pursuant to the Agreement and Plan of Merger and Reorganization, dated
: November 18, 2015, by and among Celladon, Celladon Merger Sub, Inc. and
: Eiger BioPharmaceuticals, Inc., (ii) a 1-for-15 reverse stock split of
: Celladon common stock and (iii) changing the name of the Company from “
|
|
